Hinova pharma

Hinova Pharmaceuticals Inc. (688302.SH) is a global innovative drug enterprise focused on cancer and metabolic diseases, with the mission of "Creating Good Medicine for the World". The company prioritizes providing patients with safe, effective, and affordable drugs and is committed to the research and production of innovative drugs that meet significant clinical needs and have global rights. Hinova owns four core technology platforms: the PROTAC Targeted Protein Degradation Technology Platform, the Deuterated Drug Research and Development Platform, the Targeted Drug Discovery and Validation Platform, and the Lead Compound Optimization and Screening Platform. It has undertaken two national "Major New Drug Creation" science and technology projects and multiple provincial and municipal research projects, with 10 products currently in the pipeline. The management team has extensive experience in drug research and development, and the core members mostly come from well-known Fortune 500 pharmaceutical companies. In its current product pipeline, Desenlusamide (HC-1119) is undergoing two Phase III clinical trials in China and globally for the treatment of castration-resistant prostate cancer; HP501 for the treatment of hyperuricemia/gout has completed Phase II clinical trials; HP558, which has potential therapeutic effects on gastrointestinal tumors, has completed Phase I clinical trials in Europe, and its Phase II clinical trial application has been approved by the NMPA; HP518, an oral PROTAC drug targeting AR, is currently undergoing Phase I clinical trials in Australia.